Tilray Posts Record Fiscal Year on BrewDog Deal, Medical Cannabis Growth

Revenue Milestone Anchored by Beverage Segment

Tilray Brands reported its highest annual revenue to date, with the BrewDog acquisition accounting for a material share of top-line growth. The company completed its purchase of the Scottish craft brewer in fiscal 2025, folding BrewDog's global distribution network and brand portfolio into Tilray's beverage division. The beverage segment now represents the largest share of consolidated revenue, outpacing cannabis operations for the first time in company history.

CEO Irwin Simon has positioned Tilray as a lifestyle conglomerate rather than a pure-play cannabis operator. The BrewDog deal was the capstone of that pivot. It added over 100 craft beer SKUs and a direct-to-consumer e-commerce platform. The integration appears to have met internal targets, with no material write-downs disclosed in the fiscal-year results.

Medical Cannabis Drives Margin Expansion

Tilray's medical cannabis division posted double-digit growth in Europe and Australia, with gross margins expanding 320 basis points year-over-year. The company operates cultivation facilities in Portugal and distribution partnerships in Germany, Poland, and the United Kingdom. Germany remains the largest medical cannabis market in Europe by patient count. Tilray holds supply agreements with multiple German pharmacies under the country's prescription framework.

The margin improvement reflects scale efficiencies and a shift toward higher-margin finished goods. Tilray has phased out bulk flower sales in favor of branded pre-rolls, vape cartridges, and oil-based tinctures sold under the Aphria and Broken Coast labels. Unit economics by product category weren't disclosed, but the margin trend suggests the branded strategy is working.

U.S. Cannabis Exposure Remains Limited

Tilray generated minimal revenue from U.S. cannabis operations, as federal prohibition blocks the company from touching THC products domestically. It sells CBD beverages and wellness products in the United States through its Manitoba Harvest and Happy Flower brands, but those lines remain subscale relative to the international cannabis business. Tilray has repeatedly stated it won't enter the U.S. THC market until federal rescheduling or legalization occurs.

That stance sets Tilray apart from multi-state operators like Curaleaf and Trulieve, which generate the bulk of their revenue from state-licensed dispensaries. The trade-off: Tilray avoids 280E tax penalties and maintains access to Nasdaq listing requirements, but sacrifices exposure to the largest cannabis market by consumer spend. For context on Tilray's broader financial strategy, see the CannIntel topic hub on Tilray earnings.

What Investors Are Watching Next Quarter

Tilray's next earnings call will likely focus on BrewDog integration costs and whether medical cannabis growth can offset currency headwinds in Europe. The euro has depreciated 4% against the U.S. dollar since May, which will compress reported revenue when Tilray converts its European sales. Analysts will also watch for updates on Germany's recreational cannabis pilot program, which could open a new revenue channel if Tilray secures a cultivation license.

Tilray hasn't provided formal guidance for fiscal 2027, but management has signaled continued M&A activity in both the beverage and cannabis sectors. Cash flow from the BrewDog business gives Tilray acquisition currency that most cannabis-only operators lack. Next catalyst: fiscal Q1 2027 results, expected in early October.